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Abstract
The Global Virus Network (GVN) was established in 2011 to strengthen research and responses 
to emerging viral causes of human disease and to prepare against new viral pandemics. There 
are now 52 GVN Centers of Excellence and 9 Affiliate laboratories in 32 countries. The 11th 
International GVN meeting was held from June 9–11, 2019 in Barcelona, Spain and was jointly 
organized with the Spanish Society of Virology. A common theme throughout the meeting was 
globalization and climate change. This report highlights the recent accomplishments of GVN 
researchers in several important areas of medical virology, including severe virus epidemics, 
anticipation and preparedness for changing disease dynamics, host-pathogen interactions, 
zoonotic virus infections, ethical preparedness for epidemics and pandemics, one health and 
antivirals.
1. Introduction to the GVN
The Global Virus Network (www.gvn.org) is a global coalition of leading virologists. Founded in 
2011, the not-for-profit organization GVN has grown to 52 Centers of Excellence and 9 affiliate 
institutions in 32 countries throughout the world. 
The GVN mission is to strengthen research and response to current viral causes of human 
disease and to prepare for new viral pandemic threats through the collaboration of a global 
network of expert virologists. The GVN activities are mainly based on virology research, 
training and advocacy. 
The GVN International meetings is one way to support its mission, providing a framework 
where global junior and senior virologists can connect, discuss and establish new 
collaborations and advance the field. 
Past GVN International meetings have taken place in Washington DC, USA and Dublin, Ireland 
(2011), Naples, Italy and Baltimore, MD, USA (2012), Munich, Germany and Moscow, Russia 
(2013), Beijing, China (2015), Sapporo, Japan (2016), Melbourne, Australia (2017), and France 
(2018).
The 2019 GVN International meeting took place in Barcelona, Spain, June 9-12 and was jointly 
organized with the Spanish Society of Virology. The meeting had 311 delegates from 22 
different countries. A common theme throughout the meeting was globalization and climate 
change. The 11th GVN International meeting gave GVN participants an opportunity to discuss 
recent findings in virology, thus providing a platform for collaboration and networking, 
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particularly for the high number of participating young Spanish virologists. The GVN Sessions 
will be outlined in the present report. 
In addition to plenary lectures and workshops that were held at the SEV-GVN joint meeting, 
contributions in the format of short oral presentations were arranged to include a wide 
spectrum of issues addressed by member-scientists of GVN. Poster sessions allowed an 
interesting discussion among essentially younger scientists from Spanish laboratories and 
participants from other countries. With this perspective for the first time GVN established 
travel grants that consisted of partial financial help to encourage participation of younger 
members of GVN centers. In contrast to previous GVN meetings (4-5 oral presentations on 
related subjects in each block) sessions were arranged as a series of talks that covered a quite 
diverse repertoire of issues of interest to virologists around the world.
2. The 2019 Robert C. Gallo award for scientific excellence and leadership.
Criteria for the selection of this award include: 1. The candidate has published important 
scientific information on virology in the areas of interest to the GVN, including but not limited 
to: basic science, clinical aspects, pathogenesis, epidemiology, diagnostics, antivirals, and 
vaccine development. 2. The candidate has made a consequential and meaningful contribution 
to the GVN and has furthered the mission of the GVN, including but not limited to; 
development of the network of Centers of Excellence, participation in training programs, 
contributions to meetings and other GVN activities, and contributions to advocacy and public 
communication activities.
The 2019 Robert C. Gallo award for scientific excellence and leadership was awarded to Dr. 
William Hall, GVN Co-founder.
3. Scientific presentations
3.1 Anticipation and preparedness
Scott C Weaver (University of Texas Medical Branch, USA) gave an overview on 
the history and the distribution of Zika virus (ZIKV). He summarized the recent 
epidemic of ZIKV in the Americas and depicted the association between ZIKV and 
microcephaly that was established late in 2015. He then illustrated the reaction of 
GVN with the assembly of a global Zika Task Force that was established within 
three months after the association between ZIKV infection and microcephaly was 
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recognized. This task force gathered experts on flaviviruses, arboviruses, and viral 
congenital diseases from 13 GVN centers from 13 countries. 
Besides communication of the latest information on ZIKV and the distribution of 
expert reviews (Weaver et al., 2016) the task force, which was supported by a 
private donation, established the GVN ZIKV Serum Bank. This serum bank 
collected and characterized more the 100 sera from donors who had been 
exposed in different countries all across South and Latin America. They made this 
collection of highly characterized sera available to international expert labs by 
providing lyophilized aliquots. They further provided a collection of ZIKV strains, 
different virus antigens, and two cDNA infectious clones. 
Weaver also reported on ZIKV vaccine strains that were attenuated through 
deletions in the 3’UTR. As a DNA-launched ZIKV live-attenuated vaccine, having a 
20-nucleotide deletion, this mutant virus gave rise to high antibody titers after a 
single immunization and was highly protective in a ZIKV mouse model, as well as, 
in a rhesus macaque infection model (Zou et al., 2018). 
Núria Busquets (Centre de Recerca en Sanitat Animal, Spain) highlighted the 
importance of arboviruses as pathogens and focused on the surveillance of 
vectors and animal reservoirs. She gave a short overview on the emergence of 
arboviruses which over the last 40 years has become an important global public 
health threat causing significant morbidity and mortality among humans and 
animals. While for Chikungunya, Dengue, and Zika virus carrying mosquitos easily 
can spread also other arboviruses, e.g. Rift Valley Fever virus (RVFV), and West 
Nile virus (WNV), there is a critical role for vertebrate hosts as animal reservoirs. 
Dr. Busquets stressed that good surveillance data are the base for intervention 
strategies thus helping to protect public health and to save money. Thus, detailed 
knowledge on which mosquitoe species are competent hosts for the virus and 
where and when these mosquitoes are present, as well as, on which the 
vertebrate hosts are the reservoir and their presence are important. So is the 
knowledge on the kinetics of infection, viremia and virus shedding, the immune 
response and last but not least good, reliable, and rapid diagnostic tools. She 
pointed out that virus circulation in vectors and in animal reservoirs precedes 
human exposure and infection. During an arbovirus outbreak in humans, clinical 
signs might only be detected when the peak of an outbreak has already been 
passed. However, virus circulation in vectors and the animal reservoir will precede 
human infections (Reusken et al., 2018). Therefore, early detection in vectors and 
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animal reservoir hosts can serve as an early warning system to mitigate economic 
and human health impact. How important the interplay between different 
information sources is was demonstrated in 2015 – 2016 when the combination 
of weather forecast and syndromic animal surveillance during El Nino rains in 
Kenya resulted in an effective early warning for a major outbreak of RVFV, thus 
allowing precautions to prevent spill over to humans (Oyas et al., 2018). 
As a second example she presented the WNV outbreak on the American continent 
starting in New York City in 1999 (CDC, 1999) and the emergence of WNV lineage 
2 in Spain in 2017 (Napps et al., 2019). In both cases dead bird surveillance and 
identification of equine infections was an important for WNV surveillance as an 
early warning system. Dr. Busquets concluded that arbovirus surveillance provides 
a realistic picture of the epidemiological situation and allows for monitoring the 
effectiveness of intervention measures. Surveillance in vectors and in vertebrate 
hosts enables detection of arbovirus circulation before clinical onset in humans. 
However, countries need to adapt their surveillance scheme to their 
epidemiological situation, surveillance objectives and capacities. Effective early 
warning requires the interaction between multiple disciplines like entomologist, 
veterinarians, biologists, clinicians, epidemiologists, etc.
Masao Matsouka (Kumamoto University, Japan) gave a detailed insight into 
aspects of the strategy and pathogenesis of Human T-cell leukemia virus type 1 
(HTLV-1). In his presentation he focused on two viral proteins, the transactivator 
of viral gene expression (Tax) and the HTLV-1 bZIP factor (HBZ). HTLV-1 is the 
causal agent of adult T-cell leukemia (ATL) and HTLV-1-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP) in adults. It has close relatives 
in several non-human primates and is an important human pathogen with a global 
distribution of infection foci and an estimated 10 million people are infected 
(Sonoda et al., 2011). HTLV-1 is transmitted only through cell-to-cell contact 
passing the virus from mother to infant through breast milk and from male to 
female through semen. Therefore, living infected cells are essential for 
transmission and in order to enhance transmission the virus increases the number 
of infected cells. While the cellular receptor for HTLV-1 is ubiquitous (Manel et al., 
2003) the provirus is mainly detected in CD4+ effector/memory T cells in vivo. 
However, it was not clear if HTLV-1 preferentially infects these cells or if infected 
precursor cells differentiate into these cells. Analyzing tax expression as a marker 
for viral replication in STLV-1 infected Japanese macaques as a model for HTLV-1 
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infection in humans, Matsouka and colleagues showed that elevated tax 
expression is mainly seen in the bone marrow suggesting de novo infection of 
hematopoietic stem cells (HSCs). Further, in HAM/TSP patients they detected 
identical integration sites of HTLV-1 proviruses in neutrophils, monocytes, B cells 
CD8+ T cells and CD4+ T cells indicating that these cells are all derived from HTLV-1 
infected HSCs in vivo.
While Tax has an important role in the upregulation of anti-apoptotic genes and 
the maintenance of cell populations it is only expressed transiently, most likely 
because the Tax protein is highly immunogenic and a major target for CTL. In 
leukemic cells Tax is expressed only in a minor fraction of the cells and only for a 
short period of time (Mahgoub et al., 2018). Matsouka then concentrated on the 
important role of HBZ in HTLV-1 pathogenesis. HBZ is encoded on the antisense 
strand of the provirus and has a low immunogenicity. In contrast to Tax it is 
expressed constantly in all ATL cells. HBZ regulates several different pathways in 
infected cells, enable immune escape, trigger inflammation through the induction 
of IFNg expression, and enable the infection to overcome immune suppressive 
effects. HBZ also induces expression of the chemokine receptor CCR4 allowing 
infiltration of infected T-cells into tissues. Seen that HTLV-1 is transmitted through 
cell-to-cell contact he suggested that HBZ-induced CCR4 expression enables HTLV-
1 infected cells to migrate into breast milk and into semen, thus allowing efficient 
transmission of the virus between humans.
Marion Koopmans (Erasmus MC, Netherlands) elaborated in her presentation on 
the complex interplay between man-made disturbances of ecosystems and the 
resulting increase in number and amplitude of emerging viral disease outbreaks. 
She presented several examples to underline how changes in environmental 
conditions and in human behavior can create conditions that result in an increase 
of pathogen transmission, spill-over to new hosts, broad dissemination of 
infection, and changes in viral properties. The recent Ebola outbreak in West 
Africa and the ongoing outbreak in the Democratic Republic of Congo illustrate 
how demographical and political changes can affect spreading of diseases. 
Dr. Koopmans emphasized the important role and the potential of surveillance by 
presenting preliminary results on arbovirus surveillance from the ARBO study and 
data from an influenza market surveillance in poultry in China (Bai et al., 2019). 
She also pointed out a potential role for co-circulation of different viruses, e.g. 
Zika and dengue for new pathogenesis pathways (Langerak et al., 2019). Shifting 
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the burden of disease detection from clinicians to early detection and forecasting 
of spillover through surveillance of reservoir hosts would mean a paradigm 
change in the surveillance of emerging infectious diseases from reactive to pro-
active measures. Early detection allows timely control and thus mitigates the 
number of human cases (Karesh et al., 2012). Matching these surveillance data 
with data on demographic development, global travel and trade, and climate 
change might allow to predict potential international spread of pathogens. The 
utility of such approaches will very much depend on a switch from the detection 
of single pathogens to an “open view” surveillance with multiplex assays, broad 
antibody profiling, metagenomics approaches, and an efficient way of data 
sharing.
3.2 Host-pathogen interaction.
Thomas Rasmussen, a Senior Researcher at the National Veterinary Institute of Virology in 
Australia, presented an update on the potential use of latency-reversing agents (LRAs) for HIV 
elimination. The great success of antiretroviral therapy (ART) for HIV Infection is tempered by 
the fact that treatment must be maintained for life. Rasmussen reviewed work showing that 
HIV can remain in a latent state where the immune system or ART cannot eliminate the virus.  
Rebound viremia occurs when ART is stopped even in individuals with no detectable virus in 
cells or plasma. An experimental approach to clear latent HIV and thus cure HIV infection has 
been dubbed “shock and kill.” LRAs are used to activate latent HIV allowing the reactivated 
cells to be targeted and killed by ART and/or the immune system. Administration of LRAs alone 
have thus far not demonstrated an effect on the frequency of latently infected cells or the time 
to virus rebound following interruption of ART (“shock, no kill”). For example, in the DIORR 
trial (Dolutegravir Intensification Effect On Residual virus Replication on ART) lead by 
Rasmussen there was no change in levels of HIV DNA or RNA. Negative results where 
mechanisms for failure are carefully examined are important because they can demonstrate 
which strategies will not work and provide guidance to strategies that do work. Elimination of 
latently infected cells (particularly those that are long-lived) may require HIV-specific CD8+ T 
cell effector functions similar to those of so-called elite controllers of HIV-1 infection. Various 
strategies to boost anti-HIV immunity currently under development including therapeutic 
vaccines, toll-like receptor agonists, broadly neutralizing antibodies, immune checkpoint 
inhibitors, interferon-α and interleukin therapy should be investigated. Immune checkpoint 
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blockade could also play a role in developing an HIV cure by re-invigorating exhausted T cells 
and potentially reversing HIV latency in CD4+ T cells. 
Infection by mosquito-borne viruses has increased over the past few decades due to 
globalization, increase in societal mobility and climate change. Juana Diez from the Universitat 
Pompeu Fabra in the lovely host city of Barcelona continued the session by exploring how 
viruses such as Chikungunya virus (CHIKV) are able to express their genomes at high levels in 
cells from diverse species. The four bases of the genetic code create 64 codons, of which 61 
are translated into 20 amino acids and 3 are stop codons.  Synonymous codons differ 
principally at the third base or wobble position. Different species, including mosquitoes and 
humans, vary widely in which codons are used for protein translation.  Dr. Diaz and her team 
integrated subcellular fractionation and transcriptome-wide analyses of translation in human 
cells, to show that CHIKV infection induces a host adaptation to viral codon usage into the 
endoplasmic reticulum (ER), the preferred site of CHIKV protein expression. The tRNA 
modification enzyme methyltransferase 9 (KIAA1456) methylates uridine in the wobble 
position and enhances speed of translation of certain mRNAs, including CHIKV mRNAs. 
KIAA1456 mRNA is translationally activated up to 40-fold by CHIKV infection. Overexpression 
of KIAA1456 increases CHIKV replication and KIAA1456 mRNA silencing decreases replication. 
These findings demonstrate an unexpected interplay of viruses with the host tRNA 
epitranscriptome that favors viral protein expression. This mechanism appears to be conserved 
among viruses that replicate effectively in more than a single host species, which opens the 
intriguing possibility of future exploitation of a broad-spectrum antiviral target.
3.3 Ebola virus, viral protein corona and arboviruses 
The ebolaviruses cause highly lethal disease with sporadic and unpredictable outbreaks. An 
ongoing outbreak in Democratic Republic of the Congo is the second largest in history. While 
the genome of Ebola virus encodes just seven proteins, the deleterious effects on the human 
body are immense causing severe pathology and fatalities. Thus, basic research is needed to 
understand the viral protein conformations and their role in viral replication. Sara Lenderas 
Bueno from the Scripps Research Institute explained that several of these proteins are 
multifunctional in the viral cycle, and some of these are also multi-structural, adopting 
different forms at different times to mediate different, essential functions. Using 
crystallography, electron microscopy and biochemistry, it was found that two essential 
proteins in infection; the nucleoprotein NP and the matrix protein VP40 display different 
conformations. NP is involved in viral nucleocapsid formation and facilitates viral transcription 
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and replication. To avoid premature self-polymerization and non-productive binding to cellular 
RNAs, NP is chaperoned by the viral phosphoprotein VP35. NP complexing with the amino-
terminal portion of VP35 was delineated at 2.3 Å resolution and electron microscopy indicated 
the importance of this binding interaction to control NP polymerization. Structure-directed 
mutagenesis studies identified conserved critical residues in the NP-VP35 interface which 
could be targeted by broadly effective antivirals. With regard to the matrix protein VP40, 
another multi-structural protein, it rearranges into three alternative structures, each with its 
corresponding function at different stages of the life cycle. How these structural changes are 
triggered has remained unclear. New data revealed that the binding of the VP40 dimer to 
specific nucleotide sequences is enough to form the octameric structure/form responsible for 
regulation of viral RNA replication. These findings provide the molecular basis for the 
multifunctionality of these proteins and reveal attractive targets for therapeutic intervention.
Kariem Ezzat from Stockholm University presented tantalizing data on the role of viral protein 
corona in viral pathogenesis and amyloid aggregation. Viruses rely on the intracellular host 
machinery for replication, production of viral proteins and assembly. However, outside cells, 
viruses share many biophysical properties with nanoparticles. Based on these features, viruses 
have the capacity to accumulate a host-derived protein corona layer in extracellular 
environments similar to nanoparticles. To evaluate this possibility and its implications, protein 
corona layers of respiratory syncytial virus (RSV) and herpes simplex virus 1 (HSV-1) in different 
biological fluids such as human plasma and bronchioalveolar lavage fluid were analyzed using 
proteomics, electron microscopy, infectivity, and dendritic cell activation assays. It was found 
that RSV and HSV-1 accumulate rich protein corona layers that are unique for each biological 
fluid and corona pre-coating differentially affects viral infectivity and immune cell activation. In 
addition, like nanoparticles, viruses should be able to function as nano-surface catalysts that 
enable accelerated extracellular amyloid protein aggregation. The authors also showed that 
HSV-1, which has been implicated in Alzheimer’s disease, catalyzes the nucleation and 
accumulation of the Aβ42 peptide both in vitro and in vivo. Results from Ezzat et al. 2019 
showed that unlike the viral genome coded surface proteins, the viral protein corona is an 
acquired structural layer that is dependent on the viral microenvironment resulting in different 
viral identities based on the target tissue and the target organism. Additionally, the viral 
corona-driven heterogeneous nucleation of amyloids illustrates convergence between viral 
and amyloid pathologies suggesting a direct physical mechanistic link that warrants further 
investigation.  
Ana Isabel Nunez from IRTA-CReSA, Barcelona, Spain, discussed novel findings on mosquito 
molecular responses to arbovirus infection, particularly related to Rift Valley fever phlebovirus 
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(RVFV) and Culex pipiens. In the literature, the Aedes aegypti-Dengue virus (DENV) 
combination is the most studied in terms of gene expression. However, there is a general 
paucity of information on mosquito genes involved in vector competence and immune 
responses with regard to other important vector-virus interactions.  RVFV causes an emerging 
significant public health zoonotic disease which is commonly transmitted mainly by the Culex 
and Aedes genus mosquitoes. In her talk, molecular responses of Culex pipiens to RVFV 
infection were presented, particularly those related to genes implicated in the innate 
immunity pathways (Toll, IMD, JAK/STAT) and RNAi. A total of 445 differentially expressed 
genes (DEG) were identified. The gene expression profiles varied at different days post 
infection. A total of 445 DEG were found wherein 42 DEG were immune function related. 
Among these genes, some are involved in innate immunity pathways; Cactus or Defensin-A in 
the Toll pathway or Piwi4 and Drosha in the RNAi pathway. Specifically, three immune 
pathways Toll, IMD and RNAi and apoptosis were affected by RVFV infection. Conversely, 
JAK/STAT pathway seems not to be involved in Culex pipiens response to RVFV. Toll and Imd 
pathways are suppressed after infectious blood feeding, for example AMP (Defensin-A) was 
down-regulated. The RNAi pathway was mainly down-regulated in the course of the RVFV 
infection. All these immune system responses would allow the establishment of the RVFV 
infection in Culex pipiens mosquitoes. These results form a basis for future in depth studies to 
better understand the functionality of immune related DEG in relation to vector competence 
to develop new strategies for vector control programs.
Ken Olson from Colorado State University reviewed the RNAi and arbovirus interactions. Such 
infections in Aedes aegypti allows transmission of yellow fever, dengue, Zika, and chikungunya 
viruses throughout the mosquito's lifetime. The mechanisms of viral persistence in 
mosquitoes, which involves the production of virus RNA-derived siRNAs and piRNAs, are not 
well understood. The RNA interference pathways involve double stranded RNAs that degrade 
target RNAs and mediate gene regulation. In his studies, siRNA and piRNA product depletion, 
small RNA sequencing, piRNA product expression profiles, immunoprecipitation, and arbovirus 
assays were used to dissect the viral and host-cell interactions. It was found that the Piwi-
family protein Piwi4 has antiviral activity in Aedes aegypti Aag2 cells and in mosquitoes 
infected with arboviruses and insect-specific flaviviruses. Although these RNA viruses encode 
no reverse transcriptase, circular episomal DNA in arbovirus-infected Aedes aegypti cells 
consisting of hybrid sequences of arbovirus-derived cDNA (vDNA) and retrotransposable 
elements were found. These episomal DNAs appear to be acquired during reverse-
transcription by a discriminatory process of vDNA recombination with retrotransposons. 
Transcripts from vDNA may serve as precursors for antiviral vpiRNAs. Integrated viral-derived 
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(vDNA) can also be detected in the mosquito genome as endogenous viral elements (EVEs) 
that are often associated with piRNA clusters in the mosquito genome. EVEs are transcribed to 
produce piRNAs that associate preferentially with Piwi4. Importantly, EVE-derived piRNAs can 
inhibit the replication of a cognate virus. These findings suggest that the Aedes aegypti Piwi 
family of proteins and episomal vDNA, and EVEs provide a means of moderating viral load in 
mosquito cells and a potential mechanism for transgenerational virus tolerance in the 
mosquito.
Richard Zhao from the University of Maryland presented data on the virologic differences in 
severaty between historical and epidemic Zika virus mediated infection and neurocytotoxicity. 
The 2015 Zika virus (ZIKV) outbreak in the Americas have had a severe impact as it in Brazil 
alone left >3000 babies with ZIKV-associated neurological disorders (ZAND) including 
microcephaly. Even though the causal relationship between the ZIKV and ZAND have been 
confirmed, the reasons why the ZIKV suddenly became so pathogenic and caused ZAND in 
humans remain largely unknown. To help answer this question, the virologic differences and 
the underlying molecular mechanisms between the representative historical African MR766 
ZIKV strain and the epidemic Brazilian BR15 ZIKV strain were examined. Glioma SNB-19 cell line 
and 3-D neurospheres were used to evaluate both primary and chimeric viruses. Notable 
differences were found between strains with regard to viral attachment, permissiveness and 
replication, as well as, the induction of neurocytopathic effects in host neuronal cells. Chimeric 
virus analyses suggested that the ZIKV E protein correlates with the viral attachment, and the 
C-prM region contributes to the permissiveness and ZIKV-induced cytopathic effects. 
Furthermore, the prM protein and its cleaved Pr product, but not the mature M protein, 
induces apoptotic cell death in the SNB-19 cells. The Pr region, which resides on the N-terminal 
side of prM protein, is responsible for prM-induced apoptotic cell death. Mutational analysis 
further identified four amino-acid residues that have an impact on the ability of prM to induce 
apoptosis. These findings suggest that functions of the structural prM-E proteins contribute in 
part to the difference in ZIKV-mediated viral pathogenicity between the historic and epidemic 
strains. Ongoing studies are likely to identify the role of other viral proteins with regard to 
neuropathogenesis.   
Ramesh Akkina from Colorado State University reported on the ZIKV mediated pathology on 
human hematopoietic cells. While many previous studies have focused on ZIKV viral effects on 
the CNS, few have explored the viral effects on the human immune and hematopoietic system. 
Dr. Akkina presented both in vitro and in vivo studies conducted on human cells. In vivo studies 
involved humanized mice (hu-mice) that harbor a transplanted human immune system. These 
mice generate human T cells, B cells, NK cells, monocytes and macrophages, as well as, 
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dendritic cells that orchestrate both humoral and cellular immune responses and thus are ideal 
models to examine viral effects and interactions with human immune cells (Akkina, 2013). 
Since the hu-mice also harbor human hematopoietic stem cells in the bone marrow, viral 
effects on these cells can also be ascertained. Recent studies (Schmitt et al, 2018) has shown 
that ZIKV infection of hu-mice can generate a human neutralizing antibody response to ZIKV 
and also that human B cells and CD34 HSC can be infected. In studies presented at the 
meeting, further investigations were carried out on the ZIKV infection on human B cells in vitro 
and in vivo to determine any adverse effects such as cell death or cell dysfunction, as well as, 
viral persistence. Viral exposure of mature naïve B cells resulted in the loss of one subset and 
aberrant proliferation of another.  Upregulation of markers indicative of B cell progression into 
the plasmablast stage was seen in the expanding subset. In vivo, results from ZIKV infected hu-
mice showed the presence of ZIKV+ B cells in the periphery during acute infection and later in 
bone marrow during the chronic stage. It was also found that CD34+ HSC were susceptible to 
ZIKV infection in vitro and could be detected in the bone marrow of infected hu-mice. B cell 
loss can lead to delayed viral clearance, whereas aberrant B cell activation may have 
implications in the pathogenesis of autoimmune diseases such as Guillain-Barré syndrome. 
Infection of CD34+ HSC has implications for hematopoietic cell differentiation and viral 
persistence. 
Currently several murine models of ZIKV neuropathogenesis exist. Since standard mice are not 
susceptible to ZIKV, mostly IFN deficient mice that lack an innate immune system and thus 
permitting ready viral infection are used. A significant drawback with these models is that viral 
infection leads to rapid fatalities, which is not a common feature with ZIKA. In the studies 
presented BALB/c RAG2-/-γc-/- mice (also known as BRG mice) with intact IFN pathway were 
used. Neonatal mice when exposed to ZIKV developed severe microcephaly and other 
important CZS features such as eye deformations and stunted growth. This model is likely to 
be useful as an experimental neonatal ZIKV infection model. With regard to human cell 
infections, these findings highlighted the utility of hu-mice as valuable human surrogate 
experimental system to directly assess ZIKV effects on these cells in vivo.
3.4 Preparedness for zoonotic infections, emerging infectious diseases and ethical review, 
and vaccine take in the elderly
Christopher Kratochvil, co-director of Global Center for Health Security (GCHS, University of 
Nebraska) presented the mission and resources of the center, which is an initiative of the 
University of Nebraska Medical Center (UNMC) with the purpose of leading US domestic and 
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global preparedness for emerging infectious diseases (EIDs) 
(https://www.unmc.edu/iexcel/global-center/index.html). Since its foundation in 2017 it has 
become a primary biosecurity resource for training, education, research, and clinical care and 
for advancing international capacity and innovation to prevent and mitigate the effects of EIDs 
and other public health emergencies. The program’s successes have been built upon a 
foundation of robust partnerships with diverse governmental and academic 
organizations(Ktatochvil et al., 2017; Eitzen et al., 2019). 
The GCHS has numerous resources, including a clinical biocontainment unit, a quarantine unit, 
a training and simulation center which includes a simulated biocontainment unit, as well as, 
diverse laboratory and clinical resources from across the academic health center. 
Strategic partnerships with the Assistant Secretary for Preparedness and Response (ASPR), the 
Centers for Disease Control and Prevention (CDC), the Department of Defense, and other 
academic health centers, have resulted in multiple collaborative initiatives. Examples include 
the National Ebola Training and Education Center (NETEC), the Special Pathogens Research 
Network, the U.S. Air Force C-STARS training program, the Federal Quarantine Center, a 
National Disaster Medical System training program, and a central institutional review board 
(IRB) specializing in preparedness, as well as, rapid response (NETEC, 2019). The center is open 
to global collaboration, which already includes Singapore, Germany, South Korea, and China. 
Among the relevant events Dr. Kratochvil mentioned recent workshops and training courses 
and the anticipated 2020 FDA Course “Achieving Data Quality and Integrity in Clinical Trials 
Involving High Consequence Pathogens” at the Davis Global Center 
Jordi Rodon (Food & Agriculture Science and Technology Center IRTA; Center for Animal 
Health Research CReSA, Barcelona, Spain) presented a suitable a new model to study early 
events of Middle East respiratory syndrome coronavirus (MERS-CoV) infections (van 
Boheemen et al., 2012; Cotton et al., 2014) 
MERS, a previously unreported zoonotic disease emerged in 2012. As of May 2019, World 
Health Organization has been informed of more than 2,000 laboratory-confirmed human cases 
including almost 838 fatalities (Ramadan and Shaib, 2019). It is endemic in the Middle East and 
human cases have been reported in 27 countries. Symptoms range from asymptomatic to very 
severe pneumonia with acute respiratory distress syndrome (ARDS), septic shock and 
multiorgan failure. No vaccines are commercially available nor have specific treatments been 
developed. 
Dromedaries are the natural reservoir, but alpacas have also been reported as potential hosts 
for MERS-CoV (Chan et al., 2014). Since handling dromedary camels is not an easy option, 
especially under biocointantment conditions, and based on preliminary data showing that 
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alpacas is a valuable model to study early MERS-CoV infection events, the Catalan scientists set 
out to develop an ex vivo model derived from the latter animals. Dr. Rodon described the 
isolation of respiratory tissues to assess the early local immune events elicited upon infection. 
Isolated nasal mucosa and tracheal explants were maintained in vitro and infected with MERS-
CoV/Qatar 2015. Samples obtained at different times from 0 to 96 hours post-inoculation were 
used to quantify viral RNA by RT-qPCR, detect virus antigen localization by 
immunohistochemistry (IHC) and to isolate virus. 
This work indicated that nasal mucosa and tracheal explants from alpaca are suitable ex vivo 
models to study MERS-CoV replication and molecular mechanisms leading to viral infection 
and/or virus clearance. The researchers hope to further develop the system to explore antiviral 
therapeutic approaches (Stalin Raj et al., 2018).
Wendy K. Jo(RIZ, TiHo, Hannover, Germany) described a new flavivirus (genus Pestivirus) 
detected in a toothed whales from the North Sea harbor porpoise Phocoena phocoena (Tautz 
et al., 2015). 
High-throughput data obtained by using next generation sequencing (NGS) and analyzed using 
an in-house metagenomics pipeline, followed by de novo assembly and phylogenetic analyses, 
allowed the identification of a novel pestivirus in two out of three investigated harbor 
porpoises. The complete genome of 11,880 bp, were reconstructed by de novo assembly of 
sequence reads, and confirmed by Sanger sequencing of the full-length genome. Alignment of 
the complete genomes of pestivirus species showed that the newly identified virus is 
evolutionary closest to porcine LINDA virus and porcine Bungowannah virus with 60% 
homology at the amino acid level. In situ hybridization showed strong granular staining in the 
cytoplasm of multiple cell types. Based on the new sequence information RT-PCR screening of 
samples from more than 100 stranded harbor porpoises, collected from the North Sea 
indicated that about 9% of these animals were positive for the novel pestivirus. 
The identification of a novel pestivirus in harbor porpoises suggests that the host spectrum of 
pestiviruses extends to members of the order Cetacea (whales, dolphins, and porpoises), 
which are considered to have evolved from artiodactyls (even-toed ungulates) (Jo et al., 2019). 
Elena García Sánchez (Center of Molecular Biology “Severo Ochoa”, Madrid, Spain) reported 
an outbreak of African swine fever (ASF) affecting wild boars and domestic pigs that started in 
the Caucasus in 2007 and spread across Russia and Eastern Europe. This more recent 
geographic expansion of ASF further increases the threat to the global swine industry (Karger 
et al., 2019). Dr. García Sánchez presented information on genes involved in immune evasion 
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and those hypothetically involved in attenuation of virulence of the genotype I parental ASFV 
NH/P68. Based on the information obtained, the research team generated putative live 
attenuated vaccines (LAV) prototypes by constructing recombinant NH/P68 viruses lacking 
specific genes and containing markers for DIVA tests (Gallardo et al., 2018). A bottleneck for 
the production of live attenuated virus vaccines has been the lack of permanent cell lines able 
to sustain productive virus infection. In the studies presented, porcine alveolar macrophages 
(PAM) were used to propagate the viruses. The results showed that naturally attenuated ASFV 
NH/P68 strain induced full protection against both homologous (genotype I) Lisbon 60 (L60) 
and heterologous (genotype II) Armenia07 virulent strains. The recombinant viruses carrying 
specific deletions were all fully protective against parental homologous (genotype I) Lisbon 60 
(L60) strain but only slightly protective against the heterologous (genotype II) circulating 
Armenia07 strain. More studies are required to assess the basis for the lack of heterologous 
protection of the recombinant vaccine strain, which could be related to the cell line used to 
produce the vaccine (Sánchez et al., 2019). 
Meagan Deming (Institute of Human Virology; Center for Vaccine Development and Global 
Health, Baltimore, United States) analyzed the response to hepatitis B vaccines in an aging 
population and its dependence on route of injection (Weinberger et al., 2008; Williams et al., 
2012; de Lalla et al., 1988). Fifty-two healthy adults (65-82 years; mean age 72 years), 
seronegative for hepatitis B (HBV), were recruited and enrolled by the SENIEUR protocol to 
select a strictly healthy population (Ligthart et al., 1984). These seniors were randomized to 
receive an alum-adjuvanted recombinant HepB vaccine, either subcutaneous (SC) or 
intramuscular (IM) injection, with the inoculum site guided by Computerized Tomography (CT) 
imaging. The immunological response, expressed as anti-HBs antibody titers at day 210, 
demonstrated that volunteers who received their vaccinations IM were over three-times more 
likely to be responders to the HBV vaccine than volunteers receiving SC vaccinations (54% 
versus 16%, P=0.004) (Ikeno D, et al.2010). The low seroconversion rate even in the IM group 
showed a progressive decline with increasing age of the cohort and was associated with 
significantly lower IgG2 and IgG1 isotypes suggesting a marked shift in Th1 responses. 
Moreover, the percentage of seniors that showed T-cell mediated responses was significantly 
reduced and also lower in intensity compared to young adults (Arnold et al., 2011). This study 
confirmed that SC inoculation sites markedly impair seroconversion rates probably related to 
the inoculation in the SC fat. These data show qualitative and quantitative deficits in B and T 
cell responses to alum adjuvanted protein antigens, even in strictly healthy elderly cohorts 
(Schillie et al., 2018).
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Abigail Lowe (University of Nebraska Medical Center, United States) turned the attention to 
the institutional preparedness for ethical review in scenarios of outbreaks (WHO, 2014). 
Clinical research during epidemics is crucial to build an urgent response and, yet, requires 
thoughtful oversight by research ethics committees to ensure the protection of vulnerable 
subjects facing health uncertainties. To appropriately address the regulatory aspect should be 
cultivated in anticipation of epidemics and pandemics, rather than in response to them (Alirol 
et al., 2017). The University of Nebraska Medical Center (UNMC) institutional review board 
(IRB) response during the 2014-2015 Ebola epidemic provided an example of research ethics 
review under a rapid response model. This IRB provided rapid review of multiple protocols 
during the epidemic, typically with 24 hours or less from submission to approval. Since then, 
UNMC has been developing a centralized IRB for two national networks, both focused on 
public health emergency research with a vision of establishing a rapid response resource for 
these networks (Busta et al., 2017). 
A new model is being developed to adapt it for research networks in order to pave a way for 
clinical research including early drug development for novel pathogens that may emerge in 
future outbreaks. This review model will be tested for multi-site research within the US; 
however, there is also a need to explore models for international public health emergency 
research. This process is complex from regulatory, as well as, operational perspectives and will 
only succeed with close collaborations by broad stakeholders.
3.5 One Health: fact or fiction
Jordi Figuerola (Estación Biológica de Doñana – CSIC, Spain), Albert Osterhaus (Research 
Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine 
Hannover, Germany) and Amelia Nieto (Centro Nacional de Biotecnología – CSIC, Spain) 
presented their views on the One Health concept taking into account the fields of  wildlife, 
ecology, as well as, veterinary and medical infectious disease disciplines. Figuerola highlighted 
the fundamental contribution of wildlife and environment (including climate change) to 
emerging and re-emerging zoonotic diseases, including some examples on mosquito borne 
flaviviruses like West Nile virus (Rizzoli et al., 2015), as well as, non-infectious diseases. He 
emphasized the need to further research on how organisms interact and how they interact 
with their environment as a cornerstone to understand infectious disease dynamics. Osterhaus 
covered aspects of emerging diseases in wildlife, livestock and companion animals, and the 
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role they play in emerging human infections. Subsequently he highlighted the need to 
prioritize syndrome surveillance and diagnostic platforms in humans and animals, as well as, 
the increasing role of novel molecular technologies in pathogen discovery (Kruppa et al., 
2018). In addition, he stressed that these priorities must be coupled with platforms offering 
mathematical modelling capacity, animal models and pathogenesis studies for new infections. 
Moreover, all these aspects should be accompanied by investment in therapeutics discovery 
and preventive intervention strategies. He finally emphasized a key point of the One Health 
concept, which is communication among experts, politicians, stakeholders and society 
(Reperant et al., 2015). Nieto focused specifically on one of the most devastating zoonoses in 
human history: influenza. She presented recent results showing that the heart should be 
considered a new target of influenza A viruses in addition to lung, especially by strains of high 
pathogenicity. In addition, she discussed the need for novel developments of most effective, 
ideally universal, influenza vaccines, as well as, more effective antivirals with low escape 
potential.
After their presentations, the roundtable was open to all delegates and several interventions 
took place. Some focused on the issue of communication. Most contributors agreed that 
scientists in general are not the best advocates to communicate hazards associated with 
emerging and re-emerging diseases to animals and humans alike.  Moreover, we are still in a 
reactive framework (acting once the disease is present) and should rather move towards  a 
preventive and preparedness strategy, that ideally prevents interspecies transmission of 
pathogens to occur, and if not successful provide the tools for early detection and intervention 
strategies.  Consequently, confronting emerging epidemics at the source and from the onset is 
paramount to control global infectious disease prevention and mitigation scenarios. 
Availability of adequate resources in ’peacetime’ was another hot topic, since investment in a 
preventive and preparedness scenario should be done in preparation for emerging infections, 
and not ’when the house is on fire’. Unfortunately, both at national and the international 
levels, current reality shows a generally reactive rather than proactive willingness to invest in 
preventive and preparedness scenarios. The title of the roundtable (“One Health: fact or 
fiction?”) was intentionally provocative. The impact of deadly infectious diseases is far 
different when comparing developed and developing countries, which further emphasizes the 
lack of a global, coordinated and effective agenda on One Health. Interestingly, the concept 
One Health has been highlighted regularly in the scientific literature (more than 1800 peer-
reviewed articles), but only few manuscripts propose methodologies to measure the true 
impact of the implementation of this concept. Moreover, only few suggested quantitative 
indicators to follow, but no common methodology proved to be available (Baum et al., 2017). 
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Therefore, and concluding the round-table discussion, much effort is needed by scientists, 
administration, politicians, stakeholders and citizens to truly implement the One Health 
concept at a global level.
3.6 Antivirals
Johan Neyts, Rega Institute for Medical Research, University of Leuven, Belgium, started the 
session by giving an overview of the antiviral agents now available for the treatment of 
infections with HIV, HBV, HCV, influenza and RSV infections. Dr. Neyts pointed out that for 
many other viruses that cause life-threatening infections and many of which are considered 
emerging and/or neglected pathogens, there are no drugs available. He then described the 
robotized lab-in-a-box automated platformed in a BSL3+ environment for high-throughput 
screening now installed at the Rega institute. 
Dr. Neyts presented the current state of Rega Institute’s development of potent antivirals 
against flaviviruses (such as dengue), alphaviruses (such as chikungunya) and enteroviruses as 
well as against noroviruses, the hepatitis E and the rabies virus. Several excellent molecular 
targets for the selective inhibition of viral replication (and that have remained largely 
unexplored) have been identified, such as the non-structural protein NS4B of flaviviruses, the 
capping machinery of alphaviruses and the 2C helicase of enteroviruses. The Rega Institute 
now has molecules that target the NSB4 of the dengue virus with pan-serotype antiviral 
activity in the low nM to pM range. Dr. Neyts also reported that the anti-flu compound 
Favipiravir (T705), also active against flavi-, arena-, bunya-, and filoviruses, protects mice from 
infection with chikungunya virus (CHIKV). A new class of CHIKV inhibitors, targeting viral 
capping active in the low microM range have now also been described (Delang et al., 2016; 
Gigante et al., 2014). As for entero/Rhinoviruses, besides the target for capsid binders like 
Pocapavir (Thibout et al., 2012), the researchers at the Rega Institute have found a novel 
druggable pocket formed by the viral proteins VP1 and VP2 in the virus capsid and have now 
identified analogs targeting this pocket with broad spectrum activity (Abdelnabi et al., 2019). 
Also described was a novel class of tryptophan dendrimers targeting the capsid five-fold vertex 
were found to inhibit EV-A71 replication at low nanomolar to high picomolar concentrations in 
vitro (Sun et al., 2019). A lead compound in the series (MADAL385) prevented binding and 
internalization of the virus but did not, unlike classical capsid binders, stabilize the particle. Dr. 
Neyts stated that also potent inhibitors of the enterovirus virus helicase are under way. Other 
viruses for which antiviral substances are tested for at the Rega Institute include diarrhea 
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causing viruses like human norovirus (for which zebra fish larvae has been found to be a 
replication model) and rota virus, rabies virus, and hepatitis E virus. 
Raymond Schinazi of Emory Unviversity School of Medicine presented his recent efforts to 
develop HBV capsid effectors that may offer an option to aid in a combination therapy aimed at 
curing chronic hepatitis B virus (HBV) infections.  This virus affects over 250 million people 
globally and causes 686,000 deaths worldwide per year. HBV persists due to the formation of 
covalently-closed circular DNA (cccDNA) – the viral minichromosome – in the nucleus of 
hepatocytes, and current nucleoside analogs and interferon therapies have a low rate of cccDNA 
clearance and require lifelong treatment (Schinazi et al., 2018; Schinazi and Asselah, 2017, 
Boucle et al., 2016). Dr. Schinazi’s group has identified the compound GLP-26, a novel and 
potentially best-in-class glyoxamide derivative, affecting HBV nucleocapsid formation and 
replenishment of the cccDNA pool. The drug has an EC50 in the low nM range with a 
therapeutic index of >10,000. In a humanized mouse model stably engrafted with human 
hepatocytes and infected with HBV, GLP-26 displayed a major effect on HBeAg secretion and 
HBsAg in addition to a promising pre-clinical profile. More interestingly, long term 
combination treatment with Entecavir (ETV) in this model induced a four 10log decrease in viral 
loads and viral antigens reductions that were sustained for up to 12 weeks after ceasing 
treatment. Dr. Schinazi also briefly describe the activity of novel norovirus protease inhibitors 
which were also interestingly effective against certain enteroviruses at nM levels. Enterovirus 
protease has some similarity with norovirus and coxsackievirus protease. 
María Jesús Pérez Pérez, Instituto de Química Médica (IQM) Consejo Superior de 
Investigaciones Científicas (CSIC), Spain argued that antiviral drug development has particular 
characteristics when compared to other therapeutic fields in drug discovery. As an example, it 
is indicated that phenotypic screening is still one of the main strategies do identify novel 
classes of antiviral agents while for other therapeutic areas target-based or fragment-based 
screening has often become more relevant (Murcko, J., 2018; Brown and Bostrom, 2014). Once 
a hit with antiviral properties has been identified, its optimization to become a lead is a 
multiparameter process, that can also be determined by the mechanism of action of the 
compound. Dr. Pérez Pérez’ group’s own experience in triazolopyrimidines as inhibitors of 
CHIKV replication was presented to illustrate how proactive and collaborative efforts among 
academic groups can lead to the identification and optimization of antivirals exploring a new 
mechanism of action (Gigante et al., 2014; Delang et al., 2016; Gigante et al., 2017; Gomez 
SanJuan et al.).
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Esteban Domingo, Centro de Bilogía Molecular Severo ochoa (CSIC-UAM), Spain, discussed the 
development of antiviral resistance. The evolution of viruses involves two major steps: (i) intra-
host (short-term) and (ii) inter-host (long-term) evolution. Step (i) is influenced mainly by 
random genome variations and quasispecies dynamics, and its description is based on mutant 
spectrum analyses. Step (ii) is guided by the multifactorial epidemiological fitness and 
transmission-associated random drift of genomes, and its description is based on 
phylodynamic approaches (Geoghegan and Holmes, 2018; Domingo and Perales, 2019). How 
events in step (i) influence events in step (ii) is an open question. Selection of mutants 
resistant to antiviral agents, one of the major problems in antiviral therapy, occurs at step (i) 
and its consequences are felt in steps (i) and (ii). 
Several mechanisms of selection of mutants resistant to antiviral agents have been identified 
including amino acid substitutions termed RAS (resistance-associated substitutions) at the viral 
protein targeted by the antiviral agent, and antiviral resistance mediated by high viral fitness, 
documented with hepatitis C virus (HCV). Both mechanisms affect standard inhibitors and 
mutagenic agents active in lethal mutagenesis (Perales et al. 2019). Intra-host selection of 
resistant mutants affects treatment efficacy and the choice of rescue treatments. Resistant 
mutants can acquire epidemiological relevance, therefore affecting step (ii) of virus evolution. 
Epidemiological dominance of resistant mutants may render ineffective the relevant antiviral 
agents, a problem with similarities to antibiotic resistance in bacteria. Possible approaches to 
minimize selection of escape mutants inspired in quasispecies dynamics will be suggested.
3.7 Respiratory Viruses
Leo Poon, (The University of Hong Kong), reviewed the emerging influenza viruses like H5NX 
and H7N9 circulating in southeastern China. These viruses continue to reassort with different 
avian influenza viruses and spread to other geographical locations via wild birds. Dr. Poon 
reported on a study of 96 low pathogenic avian influenza virus genomes detected from wild 
bird samples collected from 2010-2017. Their phylogeographic analysis indicated several 
independent trans-regional reassortment events during the period. All of these reassorted 
viruses acquired at least one segment from avian influenza viruses found in North/South 
America.
Yungmee Jee (National Institute of Health, South Korea) reported on the Middle East 
respiratory syndrome coronavirus (MERS-CoV) outbreaks in 2015 and 2018 in South Korea. She 
emphasized the lessons learned from their experience, which were as follows: A single, missed 
case may trigger a huge, nationwide outbreak. The first line of defense is not the thermal 
scanner at the airport, but doctors in the community clinics/hospitals. Superspreading events 
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may occur in healthcare settings, especially at the emergency department. Early detection and 
isolation are critically important. Aggressive strategy for quarantine maybe necessary, 
especially when a large number of individuals are exposed in the health-care settings.
Enric Mateu (Department de Sanitat I Anatoia Animals, Universitat Autonoma de Barcelona, 
Spain), described the virulence of and immunity against Porcine reproductive and respiratory 
syndrome virus (PRRSV) as two sides of the same problem. He emphasized that the genetic 
basis for the differences in virulence is multigenic and is related to (i) the damage caused by 
the virus, (ii) the damage caused by the immune response of the pig and, (iii) the interaction of 
the virus with the functionality of the immune system.
Neutralizing antibodies, cell-mediated immunity, ability or disability to induce type I interferon 
from macrophage and plasmacytoid dendritic cells, make the complexity of the disease 
outcome. 
3.8 influenza surveillance in Cameroon, monitoring hepatitis B virus in rural districts of India, 
virus evolution, three-dimensional cell culture infection models and new targets for antiviral 
intervention
Dr. Richard Njouom (Centre Pasteur of Cameroon, Yaounde, Cameroon) showed data of 
influenza surveillance in Cameroon for the last 10 years. Although influenza virus strains 
circulate in the country all year round, larger prevalences were observed in the rainy season, 
with a major peak between September and December. Both types of influenza (A and B) were 
detected every year, although the A(H3N2) strain was the most prevalent when all data were 
considered. Unfortunately, the surveillance system revealed that in many seasons, the 
influenza vaccine compositions available were not a good match for the types and subtypes 
that circulated in Cameroon.
Dr. Shyam Kottilil (Institute of Human Virology, University of Maryland, Baltimore, USA) 
presented their impressive efforts in monitoring hepatitis B virus (HBV) in Western districts of 
Arunachal Pradesh (India). As part of this GVN-lead program, researchers interviewed >11,800 
patients and collected >11,500 samples for HBV testing.  They found high HBV seroprevalences 
in most of the studied communities (4.8 to 12.9%), particularly in the Nyishi and Miji tribes.  An 
interesting observation was the abundance of C/D recombinant genotypes, which had been 
previously found only in the neighboring Tibet, probably a consequence of migration across 
the Chinese border.
Two studies on virus evolution were presented by Drs. Dieter Hoffmann (Technische 
Universität München, Munich, Germany) and Richard Scheuermann (J Craig Venter Institute, 
La Jolla, USA). Dr. Hoffmann and colleagues studied norovirus evolution in chronically infected 
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patients using next-generation sequencing.  They had previously shown that norovirus capsid 
gene sequences evolved quickly and accumulated non-synonymous mutations reflecting 
positive selection (Hoffmann et al., 2012). Sequentially appearing mutations correlated with 
structural changes that may lead to a decreased antibody binding. Interestingly, Dr. Hoffman’s 
group has now reported that in infected individuals, progression of the infection associates 
with increased concentrations of capsid-specific antibodies. 
The presentation by Dr. Scheuermann concentrated on enterovirus evolution. An enterovirus 
(EV) D68 outbreak in the summer of 2014 coincided with a spike in the number of cases of 
polio-like acute flaccid myelitis/paralysis (AFM). Subsequent outbreaks in 2016 and 2018 raised 
concerns about the possibility of EV D68 being a new public health threat. Comparative 
genomics analysis showed the emergence of new EV D68 lineages in recent years. Cell culture 
and animal studies revealed that these emerging viruses have acquired the ability to infect and 
kill neuronal cells (Brown et al., 2018) and cause paralysis in mice. Virion binding and cell entry 
limit the neuronal infectivity of older isolates. 
Basic research was represented by the work of Dr. Heinz Ellerbrok (Robert Koch Institut, 
Berlin, Germany) who developed new three-dimensional cell culture infection models based 
on a biological extracellular matrix (decellularized equine pericardium) with primary human 
keratinocytes (Koban et al., 2018). Using these models for studying antiviral susceptibility in 
cowpox virus infection, Ellerbrok and colleagues showed that the inhibitory potency of host-
directed epidermal growth factor receptor-blocking molecules such as gefitinib and cetuximab 
was considerably higher in three-dimensional cell culture models than in conventional two-
dimensional models, suggesting that the classical monolayer cell cultures could underestimate 
the potential inhibitory effect of an undetermined number of antiviral drugs.
Dr. Luis Menéndez-Arias (Centro de Biología Molecular Severo Ochoa, Madrid, Spain) 
presented new data on how HIV-1 reverse transcriptase (RT) connection subdomain mutations 
and non-nucleoside RT inhibitors modulate polypurine tract (PPT) removal during initiation of 
plus-strand DNA synthesis (Betancor et al., 2015). Using different HIV-1 and HIV-2 RT variants, 
this study showed that major determinants defining the correct cleavage site at the PPT/U3 
junction of the HIV genome reside at the connection subdomain between positions 342-351.  
These observations together with the fact that nevirapine, doravirine and efavirenz alter the 
efficiency of the PPT/U3 cleavage and impair the initiation of (+)-strand DNA synthesis, suggest 
that this step of reverse transcription could become a specific target for antiretroviral 
intervention. 
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
4. The Network in 2019
In 2019, GVN welcomed the following Centers and Affiliates: University of Wisconsin-Madison 
Global Health Institute, U.S. Food and Drug Administration’s Office of Vaccine Research and 
Review, the Smorodintsev Research Institute of Influenza of the Ministry of Health of the 
Russian Federation, , Manipal Institute of Virology, The Tropical Medicine Institute 
“Alexander von Humboldt” of the Universidad Peruana Cayetano Heredia, Research 
Institute of Virology Ministry of Health of the Republic of Uzbekistan, Korea National 
Institute of Health’s Center for Infectious Diseases Research, Wyss Institute for 
Biologically Inspired Engineering at Harvard University, the Antiviral Pharmacology 
Laboratory and Clinical Trials Research Center Virology Program at the University of 
Zimbabwe. 
The 6th GVN Short Course took place in Baltimore, July 29-August 2, training to date, a total of 
90 junior scientists from every continent.
The GVN is currently developing the “GVN Academy” initiative, which is an investment in a 
small group of outstanding mid-career virologist. For our pilot program, the idea is to match a 
selected number of outstanding early and mid-career from low-and-middle-income countries 
virology researchers with our senior leaders in the field to provide a series of mentoring and 
networking opportunities.
The GVN is also working on the development of Regional GVN Chapters to shift towards a 
flexible, global organization. Although the GVN is headquartered in Baltimore, it is believed 
that GVN presence needs to be truly global and therefore each GVN center needs to meet 
specific geographic challenges found particularly in Southeast Asia, South America, and Africa. 
This year, GVN has established the Africa GVN Regional Unit, in a meeting co-Organized by Dr. 
Pontiano Kaleebu, Director, UVRI and Dr. Glenda Gray, President, MRC South Africa. The 
meeting took place in Entebbe, Uganda and helped delineate collaboration as well as plan for 
future joint training initiatives.
During 2019 GVN has continued to provide public education and expert perspectives on 
current topics, such as the Ebola outbreak in the DRC.
Under the Anticipation and Preparedness Task Force umbrella, several Virus Watch Groups 
have been established, meeting regularly to discuss recent advances and findings in the field, 
monitoring viruses and virus research to ensure its efficacy and reinforce the GVN capacity.
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5. Plans for 2020
We are in the process of organizing the GVN’s 12th International meeting in Medellin, 
Colombia. This will be a unique opportunity to increase collaborations between the South 
American Regional GVN and GVN centers from other parts of the globe.
Plans are underway for the South East Asia Regional GVN kickoff meeting. This is an effort lead 
by Drs. Sharon Lewin and Linfa Wang.
GVN will continue fostering collaborations among its members, for example through joint 
grant applications and implementing various activities from the Anticipation and Preparedness 
Task Force and well as the Virus Watch Groups.
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